Live Earnings Conference Call: Ardelyx will host a live Q1 2025 earnings call on May 1, 2025 at 4:30PM ET. Follow this link to get details and listen to Ardelyx's Q1 2025 earnings call when it goes live. Get details. Ardelyx (ARDX) Competitors $5.48 -0.03 (-0.45%) Closing price 03:59 PM EasternExtended Trading$4.42 -1.06 (-19.40%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ARDX vs. GRFS, CYTK, KRYS, ELAN, PCVX, RYTM, PTCT, RNA, ZLAB, and RAREShould you be buying Ardelyx stock or one of its competitors? The main competitors of Ardelyx include Grifols (GRFS), Cytokinetics (CYTK), Krystal Biotech (KRYS), Elanco Animal Health (ELAN), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Zai Lab (ZLAB), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Ardelyx vs. Grifols Cytokinetics Krystal Biotech Elanco Animal Health Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Avidity Biosciences Zai Lab Ultragenyx Pharmaceutical Ardelyx (NASDAQ:ARDX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership. Does the media favor ARDX or GRFS? In the previous week, Ardelyx had 5 more articles in the media than Grifols. MarketBeat recorded 11 mentions for Ardelyx and 6 mentions for Grifols. Grifols' average media sentiment score of 1.36 beat Ardelyx's score of 1.06 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Grifols 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, ARDX or GRFS? Grifols has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdelyx$333.62M3.92-$39.14M-$0.16-34.28Grifols$7.21B0.67$64.20M$1.176.00 Does the MarketBeat Community believe in ARDX or GRFS? Ardelyx received 187 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 67.46% of users gave Ardelyx an outperform vote while only 56.09% of users gave Grifols an outperform vote. CompanyUnderperformOutperformArdelyxOutperform Votes53767.46% Underperform Votes25932.54% GrifolsOutperform Votes35056.09% Underperform Votes27443.91% Do institutionals & insiders believe in ARDX or GRFS? 58.9% of Ardelyx shares are owned by institutional investors. 5.9% of Ardelyx shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, ARDX or GRFS? Ardelyx has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Do analysts rate ARDX or GRFS? Ardelyx currently has a consensus target price of $10.61, suggesting a potential upside of 93.46%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardelyx 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.00Grifols 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is ARDX or GRFS more profitable? Grifols has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Grifols' return on equity of 0.00% beat Ardelyx's return on equity.Company Net Margins Return on Equity Return on Assets Ardelyx-11.73% -24.87% -10.51% Grifols N/A N/A N/A SummaryArdelyx beats Grifols on 10 of the 19 factors compared between the two stocks. Get Ardelyx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDX vs. The Competition Export to ExcelMetricArdelyxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.31B$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-34.447.4422.5118.48Price / Sales3.94242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book7.556.516.774.25Net Income-$39.14M$143.21M$3.22B$248.23M7 Day Performance9.76%1.98%1.45%0.89%1 Month Performance15.03%6.89%3.97%3.53%1 Year Performance-16.64%-2.52%16.14%5.08% Ardelyx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDXArdelyx4.5698 of 5 stars$5.49-0.5%$10.61+93.5%-13.9%$1.31B$333.62M-34.2890Positive NewsGRFSGrifols3.9001 of 5 stars$7.15-0.8%N/A+8.1%$4.92B$7.21B6.1126,300CYTKCytokinetics4.1774 of 5 stars$41.22+2.0%$79.13+92.0%-30.1%$4.91B$18.47M-7.66250Upcoming EarningsInsider TradeKRYSKrystal Biotech4.9107 of 5 stars$169.73+1.0%$222.71+31.2%+10.9%$4.90B$290.52M56.77210Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoveragePositive NewsELANElanco Animal Health3.9447 of 5 stars$9.51+0.5%$14.67+54.2%-28.0%$4.72B$4.44B23.789,800Upcoming EarningsShort Interest ↑PCVXVaxcyte3.0357 of 5 stars$32.90-0.1%$136.50+314.9%-40.8%$4.24BN/A-7.15160Upcoming EarningsPositive NewsRYTMRhythm Pharmaceuticals3.7061 of 5 stars$64.41+1.0%$74.92+16.3%+64.0%$4.07B$130.13M-14.88140Upcoming EarningsPositive NewsPTCTPTC Therapeutics4.0723 of 5 stars$49.76+0.5%$63.92+28.5%+55.0%$3.92B$806.78M-8.381,410Upcoming EarningsAnalyst RevisionNews CoveragePositive NewsRNAAvidity Biosciences2.8518 of 5 stars$31.21+1.2%$66.69+113.7%+35.3%$3.75B$10.90M-10.84190Upcoming EarningsPositive NewsZLABZai Lab2.1548 of 5 stars$32.43+1.3%$47.37+46.1%+100.6%$3.57B$398.99M-11.711,950Upcoming EarningsRAREUltragenyx Pharmaceutical4.3496 of 5 stars$37.98-0.3%$92.79+144.3%-8.4%$3.57B$560.23M-5.991,310Upcoming EarningsShort Interest ↑Positive News Related Companies and Tools Related Companies GRFS Competitors CYTK Competitors KRYS Competitors ELAN Competitors PCVX Competitors RYTM Competitors PTCT Competitors RNA Competitors ZLAB Competitors RARE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ardelyx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARDX Stock Free ARDX Stock Alerts